Navigation Links
Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
Date:10/24/2009

ALBUQUERQUE, N.M., Oct. 23 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD), a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer. The next stage of the Phase II trial calls for Biomoda to begin testing samples from already-diagnosed lung cancer patients in accordance with the study protocol approved by the U.S. Food and Drug Administration (FDA).

"More than 500 veterans volunteered to be screened with the Biomoda assay. It has been heartening to see so many men and women who served their country in the armed forces willing to help once again by participating in this important study," said John Cousins, President of Biomoda. "The study is not complete, but we are pleased with the progress to date and expect to have final data in the first half of 2010."

The Biomoda diagnostic, trademarked under the name CyPath®, is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample that is screened for cancer cells with both the CyPath® assay and traditional Pap staining. Participants also undergo a CT scan.

Dr. Thomas Bauer, chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, in Delaware, is the Principal Investigator overseeing the Phase II clinical trial. He has lead several lung and esophageal cancer studies and heads up Christiana's participation in the International Early Lung Cancer Action Program (I-ELCAP).

Based in Albuquerque, NM, Biomoda is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer.

SOURCE Biomoda, Inc.


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Lab Products Magazine Features Biomoda
2. FDA Reviewing Biomoda Submission for Cancer Screening Study
3. Small Business Innovation Research Program Awards Grant to Biomoda
4. Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting
5. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
6. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
7. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
8. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
9. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
10. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... -- ... Washington DC ... 12 th – Monday, September 18 th .The Brain Tumor Foundation ... scans to the public.Where:  BTF,s Mobile MRI Unit ... Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris ... focused on fulfilling the promise of precision medicine, ... validate the benefits of its molecular profiling approach ... utilized comprehensive genomic profiling plus (CGP+) with Caris ... patient,s tumor on a molecular level, leading to ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... 26, 2017 , ... As hurricane relief efforts continue throughout ... bras and maternity garments to women in isolated shelters. Distribution is being handled ... affiliation with Black Mothers’ Breastfeeding Association. Leading Lady’s philanthropic donation includes items from ...
(Date:9/26/2017)... ... 2017 , ... SyncDog, Inc. , the leading ISV ... software house EBF GmbH . Since 1994, EBF has been successfully realizing ... SyncDog to distribute EBF Migrator product in the U.S. and Canada. , ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... an additional two years, extending the company’s commitment to the world’s first all-diabetes ... 2012, Danish pharmaceutical company Novo Nordisk partnered with the professional cycling team Team ...
(Date:9/26/2017)... ... September 26, 2017 , ... CGL Electronic Security Inc., ... under its new umbrella, CGL Technologies, LLC. , The new CGL Technologies, LLC office ... Patitucci and Jon McCormack, both of whom have creative business development methods, who are ...
(Date:9/26/2017)... ... 2017 , ... As the holiday season nears, best deals online ... trying to find tips and stories for products and services savings. With a lot ... trending deals. The deals are organized by categories so can easily find what you’re ...
Breaking Medicine News(10 mins):